Minnesota-based medical device manufacturer
) recently reported the first implants of cardiac resynchronization
therapy (CRT) devices in heart failure patients as part of the
The primary objective of the clinical trial is to draw a
comparison between cardiac patients implanted with CRT devices
comprising the AdaptiveCRT software and those receiving
conventional CRT. The study will be carried out on the basis of two
endpoints - patient mortality rate and rate of hospitalizations for
worsening heart failure.
A cardiac patient requires CRT when his/her heart develops
arrhythmia or irregular heart rhythms. A CRT pacemaker emits small,
undetectable pulses of electricity to the two lower chambers of the
heart to help them beat together in a more synchronized pattern.
Consequently, the heart's ability to pump blood and oxygen to the
Medtronic's pioneer AdaptiveCRT software, available in its Viva
XT CRT-D (CRT devices with defibrillation), delivers customized
physiologic pacing. This procedure works by maintaining normal
heart rhythms and automatically adjusts it as per patients'
The primacy of the AdaptiveCRT algorithm will be evaluated in
the AdaptResponse trial. Presumably, this is the largest CRT trial
till date with enrollment tolling approximately 3,000 patients
across the globe.
The trial will analyze if the enrolled patients suffer from
atrial fibrillation (AF). Secondary endpoints involve measuring the
cost efficiency of CRT devices with the AdaptiveCRT feature versus
standard CRT devices.
Enrolled patients will be provided either a CRT-pacemaker or
CRT-defibrillator incorporated with the AdaptiveCRT algorithm. A
follow-up will be conducted on them at 3 and 6 months after surgery
and thereafter, every 6 months until the end of the trial.
Patients will be enrolled at 200 centers in Europe, Latin
America, the Middle East, Australia, Canada, India, Japan, South
Korea, Taiwan and the U.S.
Medtronic presently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical products industry include ICU
Medical, Inc. (
), Abaxis, Inc. (
) and Conatus Pharmaceuticals Inc. (
). While ICU Medical sports a Zacks Rank #1 (Strong Buy), both
Abaxis and Conatus hold a Zacks Rank #2 (Buy) each.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis
CONATUS PHARMA (CNAT): Free Stock Analysis
To read this article on Zacks.com click here.